Htlv 1 Associated Myelopathy (Ham) Tropical Spastic Paraparesis (Tsp) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HTLV-1 Associated Myelopathy (HAM), also known as Tropical Spastic Paraparesis (TSP), is a rare chronic progressive myelopathy caused by infection with the human T-lymphotropic virus type 1 (HTLV-1). This disorder is characterized by chronic inflammation of the spinal cord leading to progressive motor dysfunction, primarily affecting the lower limbs.[1]
HAM/TSP is the most common neurological complication of HTLV-1 infection.[2] The disease typically presents in adulthood, with progressive spastic weakness in the lower extremities, bladder dysfunction, and sensory disturbances. The pathophysiology involves immune-mediated damage to the spinal cord, particularly affecting the lateral and posterior columns.[3]
Key features include:
HTLV-1 is endemic in several regions worldwide, including:
The lifetime risk of developing HAM/TSP among HTLV-1 carriers is approximately 0.5-4%, with a higher risk in women and those who acquire infection through breastfeeding in infancy.[2] The disease typically develops 30-50 years after initial HTLV-1 infection.[7]
HTLV-1 is a retrovirus that primarily infects CD4+ T lymphocytes. The virus establishes a lifelong infection through integration of its proviral DNA into the host genome. In HAM/TSP, the immune system's response to HTLV-1 antigens triggers chronic neuroinflammation.[3]
The pathogenesis involves:
Diagnosis is based on the WHO diagnostic criteria:
No definitive disease-modifying treatment exists. Therapeutic approaches include:
Immunomodulatory therapies:
Antiviral therapy:
The disease follows a chronic progressive course over decades. Most patients require assistive devices (canes, walkers, wheelchairs) within 10-20 years of symptom onset.[7] Life expectancy is generally normal, but quality of life can be significantly impacted by disability.
While HAM/TSP is primarily an infectious inflammatory disorder, it shares features with neurodegenerative diseases:
Research into HTLV-1 pathogenesis has provided insights into immune-mediated neurodegeneration relevant to conditions like ALS and multiple sclerosis.[4]
Current research focuses on:
The study of Htlv 1 Associated Myelopathy (Ham) Tropical Spastic Paraparesis (Tsp) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gessain A, Vernant JC, Maurs L, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;2(8452):407-410. PMID:2862418
Jacobson S, Gessain A, Osame M. Human T lymphotropic virus type I and its disease associations. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S236-S242. PMID:8797715
Jacobson S, Shimizu Y, Remington K, et al. HTLV-I specific cytotoxic T lymphocytes and disease progression in HAM/TSP. AIDS Res Hum Retroviruses. 1992;8(12):1889-1894. PMID:1486215
Sato K, Kubota R, Ohya Y, et al. Mechanisms of immune-mediated neuronal damage in HTLV-I-associated myelopathy. Brain Pathol. 2013;23(5):516-529. PMID:23574353
Matsuura K, Yamano Y, Jacobson S. Neuroimaging of HTLV-1-associated myelopathy/tropical spastic paraparesis. Neuroimaging Clin N Am. 2011;21(4):817-827. PMID:22032508
WHO. Human T-lymphotropic virus type I: WHO fact sheet. WHO. 2023.
Olindo S, Smadja D, Cabre P, et al. Long-term course of HTLV-1-associated myelopathy/tropical spastic paraparesis in a cohort of 203 patients. J Neurol. 2006;253(4):510-515. PMID:16341514
Gout O. Diagnosis and course of hereditary spastic paraplegias and tropical spastic paraparesis. Rev Neurol (Paris). 2005;161(11):1033-1041. PMID:16305614